371P Palbociclib plus endocrine therapy in clinically relevant HR+/HER2- mBC subgroups: A real-world multicenter studyR. Buonaiuto, C. De Angelis, R. Esposito et al.|ESMO Open|2025Cited by 0
373P Association between CDK4/6 inhibitor (i) clinical outcomes and breast cancer (BC) histotypesClaudia von Arx, Michelino De Laurentiis, Alessandra Calabrese et al.|ESMO Open|2025Cited by 0
209P Comparative analysis of clinician and AI decision-making in HR+/HER2- early breast cancer within routine clinical practice and clinical trialR. Buonaiuto, Mario Giuliano, Pietro De Placido et al.|ESMO Open|2025Cited by 0
RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancerFlavia Jacobs, Alberto Zambelli, Salvatore D’Amico et al.|ESMO Open|2025Cited by 0